ecancermedicalscience

Short Communication

Pathologic complete response and survival in early-stage HER2-positive breast cancer patients treated with or without anthracyclines

6 May 2026
Francisco Acevedo, Benjamín Walbaum, Lidia Medina, Maritza Abud, Roger Gejman, Pablo Zoroquiain, Francisco Domínguez, Mauricio Camus, Catalina Vargas, Marisel Navarro, Constanza Pinto, Catalina Muñoz, Manuel Manzor, César Sánchez

The development of novel human epidermal growth factor receptor type-2 (HER2)-targeted therapies for HER2-positive breast cancer (HER2+ breast cancer (BC)) in recent decades has called for a reassessment of the benefit of including anthracyclines in neoadjuvant regimens, given their association with cardiotoxicity and secondary malignancies. Our study assessed the value of adding anthracyclines in a real-world cohort of early-stage HER2+ BC patients treated with trastuzumab with or without pertuzumab. We retrospectively evaluated 446 patients with early-stage HER2+ BC treated with neoadjuvant chemotherapy at two Chilean centers between 2010 and 2023. Patients received trastuzumab alone or trastuzumab plus pertuzumab, with anthracycline-containing or anthracycline-free regimens. Our primary endpoint was pathological complete response (pCR; ypT0/is ypN0). Secondary endpoints included invasive disease-free survival (iDFS) and overall survival (OS). Multivariate models assessed the predictive role of anthracyclines and pathological biomarkers (ER status, Ki67, HER2 amplification). Elevated Ki67, low ER expression and increased HER2 amplification were independent predictors of pCR. The addition of anthracyclines did not significantly improve pCR rates, even among patients treated with single HER2 targeted therapy (trastuzumab alone). With a median follow-up of 47 months, anthracyclines had no impact on iDFS (log-rank p = 0.19) or OS (p = 0.96). Subgroup and interaction analyses confirmed no benefit in other biomarker-defined populations. Overall, anthracyclines did not improve response to treatment or survival in HER2+ BC, even without dual HER2 blockade. These findings support anthracycline-free regimens, even in health systems with limited access to dual HER2-blockade with pertuzumab.

Related Articles

Nikhil Bathija, Rohit Mahajan, Anil Kumar Goel, Siva Ranjani, Mounika Sirimalla, Gourav Kaushal, Sapna Marcus, Shilpa Jain, Madhur Verma, Deep Shikha, Korukonda Vinod Kumar, Jyoti Sharma
Gbenro E. Olukiran, Adewumi O. Alabi, Anthonia C. Sowunmi, Babatunde Fadipe, Gbenga O. Popoola, Sunday A. Okinbaloye, Hnin L. Nwe Thein, Ololade Kehinde
Neha Singh, Sujata Agrawal, Zachariah Chowdhury, Shashikant Patne, Ipsita Dhal, Paramita Paul, Sadaf Haiyat, Akhil Kapoor, Anuj Gupta, Bal Krishna Mishra, Mayank Tripathi, Bipinesh Sansar
Prasanth Srinivasan, Gargi Das, Balaji Thiruvengadam Kothandan, Gautam Vydia Vedagiri, Anand Raja, Venkatraman Radhakrishnan
M P Arun Krishnan, R Nandini Devi, Praveen Kumar Shenoy, Shoaib Nawaz, Abhilash Menon, Anu Mathew